Poster presented at the Addiction Health Services Research Conference (AHSR) conference, New York City, NY, October 17-19, 2012.
Hannah K. Knudsen, PhD (University of Kentucky), Paul M. Roman, PhD (University of Georgia).
Opportunities to effectively treat alcohol use disorders (AUDs) are enhanced by the availability of pharmacological treatments. Although research has examined the organizational correlates of medication adoption (i.e., any use), less is known about the factors associated with implementation of medications to treat addiction (MAT). Implementation refers to the percentage of patients who actually receive medications. This study of community treatment program (CTPs) affiliated with the National Drug Abuse Treatment Clinical Trials Network (CTN) examined MAT implementation, defined as the total percentage of patients with AUDs who received oral tablet naltrexone, acamprosate, or long-acting depot naltrexone, with a focus on whether greater reliance on certain types of financial resources was associated with greater MAT implementation. Multivariate models were estimated for each financial factor examined, while controlling for number of physicians and the percentage of master's-level counselors. Two financial factors were significant in the adjusted models. Greater reliance on private insurance funding was positively associated with MAT implementation, while greater reliance on a Federal block grant was negatively associated with MAT implementation.
Conclusions: Naltrexone and acamprosate were rarely used in specialty settings to treat patients with alcohol use disorders. Implementation was greater in programs that relied more heavily on private insurance, while reliance on the Federal block grant was a barrier to implementation. These findings differ from the authors' prior analysis of medications for opioid use disorders, in which these sources of funding were not associated with implementation. Taken together, these two studies suggest that different types of funding may have varying implications for the implementation of medications to treat addiction. (Poster, PDF, English, 2012)
Keywords: Acamprosate | Alcohol | CTN platform/ancillary study | Health services research | Naltrexone | Pharmacological therapy | Addiction Health Services Research (AHSR) conference, 2012
Document No: 965
Submitted by Hannah Knudsen, PhD, University of Kentucky, 3/5/2013.